SCHEMBL4063754

SCHEMBL4063754

CS(=O)(=O)Nc1cccc(-c2cc3ncnc(NCc4ccc5c(c4)OCO5)c3s2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 10/20 0.52
CYP1A2 P05177 6/20 0.50
CYP3A4 P08684 6/20 0.50
CYP2D6 P10635 6/20 0.50
CYP2C19 P33261 6/20 0.50
USP2 O75604 5/20 0.50
CYP2C9 P11712 5/20 0.50
MAPK1 P28482 4/20 0.50
KDM4E B2RXH2 4/20 0.50
HPGD P15428 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 3/20 0.50
HIF1A Q16665 3/20 0.50
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TSHR P16473 3/20 0.50
RAF1 P04049 1/20 0.50
CLK4 Q9HAZ1 6/20 0.49
HSD17B10 Q99714 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13935772 0.87 PDE5A (0.53) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3937335 0.87 BRAF (0.56) PDE5ACLK4
SCHEMBL5473149 0.86 PDE5A (0.63) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4075044 0.85 PDE5A (0.60) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4074284 0.85 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL4074714 0.84 PDE5A (0.59) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4069657 0.84 PDE5A (0.61) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3933679 0.83 CLK4 (0.59) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4068212 0.83 CLK4 (0.69) PDE5ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3927433 0.83 FYN (0.55) PDE5AMEN1KMT2ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 PDE5A 1018/4885CYP1A2 137/4885CYP3A4 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.